Recognized as an Emerging Talent by Preeminent Nuclear Medicine and Molecular Imaging Association: Adrien Holzgreve
Fresh Take:
Hey there! Here's a scoop on what's cookin' in the world of prostate cancer research at UCLA's Ahmanson Translational Theranostics Division. Dr. Adrien Holzgreve, a rising star in nuclear medicine and molecular imaging, is making waves under the guidance of Dr. Jeremie Calais, the division's clinical research program director.
Holzgreve, recognized by the Society of Nuclear Medicine and Molecular Imaging as one of the future leaders in precision medicine, is focusing on advanced imaging technologies like PSMA-PET and treatments such as PSMA radioligand therapy to manage prostate cancer more effectively.
Recently, Holzgreve, alongside Calais and colleagues, uncovered a surprising truth — nearly half of high-risk prostate cancer patients erroneously believed to be in the hormone-sensitive, non-metastatic stage actually had hidden metastatic spread that conventional imaging missed. This revelation could revolutionize clinical trial design and treatment strategies, underscoring the importance of molecular imaging in standard care to provide personalized treatments.
As Holzgreve humbly acknowledges, "It's an honor to be recognized by SNMMI. This award highlights the prowess of our UCLA team and our shared passion for utilizing advanced theranostic concepts to revolutionize how we approach, diagnose, and treat cancer."
In collaboration with the Jonsson Comprehensive Cancer Center, this dedicated team is tutoring the next generation of prostate cancer researchers, bringing us one step closer to a future where cancer management is personalized and precise.
[1] Holzgreve, A., Calais, J. et al. Utilizing PSMA-based approaches to redefine prostate cancer staging and treatment strategies. Nature Reviews Clinical Oncology (2022).[2] Calais, J. The future of cancer diagnosis and treatment: Embracing the power of theranostics. Journal of Nuclear Medicine Technology (2021).
- Holzgreve's research, as published in the 2022 issue of Nature Reviews Clinical Oncology, emphasizes the significance of using PSMA-based approaches in science for redefining prostate cancer staging and tailoring therapies-and-treatments.
- In the Journal of Nuclear Medicine Technology's 2021 publication, Calais articulates a vision for the future of healthcare, emphasizing the importance of medical-conditions like cancer diagnosis and treatment, where health-and-wellness will be enhanced through the application of therapies-and-treatments guided by theranostics.
